PCN63 EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATION TESTING AND FIRST LINE TREATMENT WITH GEFITINIB IS A DOMINANT STRATEGY IN THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)

Journal article

Open access

Peer reviewed

Value in health, Vol.14(3), pp.A166-A166

2011

Files and links (1)

url

https://doi.org/10.1016/j.jval.2011.02.918View

Published (Version of record) Open

6 Record Views

Title: PCN63 EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATION TESTING AND FIRST LINE TREATMENT WITH GEFITINIB IS A DOMINANT STRATEGY IN THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
Creators: G de Lima Lopes - Johns Hopkins University
Publication Details: Value in health, Vol.14(3), pp.A166-A166
Publisher: Elsevier Inc
Academic Unit: Miller School of Medicine; UMMG Dept of Medicine - Hematology/Oncology
Language: English
Resource Type: Journal article
Record Identifier: 991031713258602976